Orforglipron has not yet been approved by regulators in the UK, US or Europe, though the US Food and Drug Administration is reviewing it
However, Wegovy (the same semaglutide molecule at weight-loss doses) is FDA-approved for chronic weight management
Other symptoms: including fatigue, vomiting, abdominal pain, growth retardation, weight loss, etc
At the same time, every claim about human efficacy tendon healing, gut repair, bone recovery remains extrapolated from rodent studies conducted predominantly by a single research group without independent replication
[PMID: 41586832] PubMed record related to this compound for laboratory literature review